Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT05240326 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

The Effects of Pilates Training on Exercise Capacity and Respiratory Muscle Performance in Patients With Rheumatoid Arthritis

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with significant functional impairment and increased risk for cardiovascular and pulmonary disease. Along with pharmacological therapy, exercise seems to be a very promising intervention to improve disease-related outcomes, including functional capacity and systemic manifestations. Despite the fact that aerobic and strengthening exercises have been shown to be useful in patients with RA, there have been limited research on the effects of pilates training. Therefore, we aimed to investigate the effect of clinical pilates training on exercise capacity, respiratory and peripheral muscle strength, respiratory muscle endurance, respiratory function, pain, balance, core stability, dyspnea, functional status, fatigue, quality of life, depression and anxiety in patients with RA.

NCT ID: NCT05238896 Terminated - Clinical trials for Rheumatoid Arthritis

BARIcitinib Cognitive Emotional and Neural signaTuRE

BARICENTRE
Start date: June 27, 2022
Phase: Phase 4
Study type: Interventional

Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has been shown to as an efficient treatment in placebo-controlled trials, and compared to the reference treatment with TNF inhibitor (adalimumab). Its efficacy has been reported on the inflammatory parameters, but more importantly on patient-reported outcomes. Baricitinib is thought to have anti-inflammatory effects, via its inhibition of the JAK pathway. Importantly, it has also been suggested to affect mood and pain. Hypotheses: Inhibition of JAK Kinase pathway in patients with RA will improve emotional and cognitive processing involved in mood disorders and decrease pain sensitization. The primary objective of this study is to evaluate early emotional impact of the JAK 1/2 inhibitor Baricitinib assessed by a facial emotion recognition task. This precocious effect on emotion processing is a surrogate marker of clinical imporvement in mood. Phase 4 study, Double-blind randomized control study with patients receiving placebo or baricitinib for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks.

NCT ID: NCT05236491 Recruiting - Clinical trials for Rheumatoid Arthritis

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

COVBIRD
Start date: March 9, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate their disease. Fear of vaccine-related disease reactivation is not of concern in other immunosuppressed groups (e.g. patients receiving chemotherapy or hemodialysis) but in SARDs, disease flare could lead to organ failure or even death. Specific research in this population is therefore critical. Moreover, among SARD patients, those on anti-CD-20 monoclonal antibody (mAb) (i.e. rituximab (anti-CD-20 mAb)), a medication used to treat inflammatory types of arthritis, have extremely low immunity post-COVID-19 mRNA vaccine. This study will test the hypothesis that a booster dose of a COVID-19 vaccine is safe and enhances post-vaccine humoral and cellular responses in SARDs patients on anti-CD-20 mAb treatment. The magnitude of this response depends on the type of COVID-19 vaccine administered and is optimal when the booster dose is a vaccine from a different group than the one used for primary immunization (mix-and-match approach).

NCT ID: NCT05232396 Completed - Clinical trials for Rheumatoid Arthritis

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Start date: March 2, 2021
Phase: Phase 1
Study type: Interventional

This is a single-dose,multi-center, randomized, double-blind, positive-controlled and parallel group clinical study that aims to evaluate the safety,tolerability,PK/PD characteristics and Preliminary Efficacy of Recombinant Humanized IL-6R Monoclonal Antibody Injection in Patients With Active Moderate-to-Severe Rheumatoid Arthritis.

NCT ID: NCT05227885 Completed - Clinical trials for Rheumatoid Arthritis

The Effects of Nutritional on Disease Activity and Functional Status in RA

Start date: December 20, 2021
Phase:
Study type: Observational [Patient Registry]

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, inflammatory disease. RA is a chronic inflammatory disease in which many patients cannot achieve remission despite current pharmacological treatments. Chronic inflammation in RA causes an increase in metabolic index and nutritional requirements. In recent studies, it is mentioned that diet regimens and foods consumed in nutrition affect inflammation. The aim of this study is to evaluate the nutritional status and habits of patients with RA and to examine their effects on disease activity level, quality of life and functional status. A questionnaire form will be applied to collect data on demographic information, disease activity, nutritional status and habits, physical activity status and physical functional status of the patients included in the study.

NCT ID: NCT05220423 Completed - Clinical trials for Rheumatoid Arthritis

Effectiveness of SMS Reminders on Influenza Vaccination Coverage in Patients With RA in the ART Registry

Start date: October 19, 2021
Phase: N/A
Study type: Interventional

Biotherapies have significantly improved the prognosis of rheumatoid arthritis (RA), particularly anti-TNF. However, these molecules are associated with a well-demonstrated increase in infectious risk, including an over-risk of pneumococcal and influenza infection.. Therefore, when initiating anti-TNF treatments, it is recommended to update the vaccination schedule of these patients, to vaccinate them against pneumococcus and carry out an annual anti influenza vaccination.. However, vaccination coverage remains sub-optimal. The means to improve this vaccination coverage are multiple but often require human resources. Medical teams often lack time, nursing interventions are effective but again requires the availability of the health care team. The use of modern digital means (automatic reminders) is an attractive alternative to increase immunization coverage without the use of medical or paramedical time. The objective of the study is to evaluate the effectiveness, in terms of immunization coverage, of SMS and/or email reminders reminding the need to vaccinate against seasonal influenza compared to usual care, in patients with RA on biotherapies participating in the e-cohort of the French ART Registry (NCT03062865). This study will be based on the ART Registry e-cohort. This will be a randomized controlled trial in patients in the ART e-cohort. The patients will be allocated in one of the 2 arms : one arm receiving reminders by email and SMS of the influenza vaccination, the other arm with absence of reminders. This study will be conducted during the annual French National communication campaign to encourage influenza vaccination. The main evaluation criterion will be the influenza vaccination coverage rate at the end of the vaccination campaign. It will be compared between the two arms.

NCT ID: NCT05219214 Recruiting - Clinical trials for Rheumatoid Arthritis

China Rheumatoid Arthritis Registry of Patients With Chinese Medicine

CERTAIN
Start date: September 1, 2019
Phase:
Study type: Observational

A multi-center registration study of clinical characteristics of rheumatoid arthritis (RA) patients with Chinese medicine.

NCT ID: NCT05215509 Completed - Clinical trials for Rheumatoid Arthritis

Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During IL-6 vs. TNF Antibody Therapy

RABEX
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The present study will investigative the physiological effects of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with rheumatoid arthritis. The investigators hypothesize that blockage of IL-6 receptors will decrease the cardiac and metabolic adaptations to exercise training compared to the inhibition of TNF. 80 patients will be included in a 12-week investigator blinded randomised exercise training intervention study.

NCT ID: NCT05214690 Completed - Clinical trials for Rheumatoid Arthritis

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

Start date: August 13, 2020
Phase: Phase 1
Study type: Interventional

Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study

NCT ID: NCT05214677 Completed - Clinical trials for Rheumatoid Arthritis

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

Start date: August 15, 2020
Phase: Phase 1
Study type: Interventional

Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study